Metraipolis › archive › dc_cf972de85d57

ADAM17 as a promising therapeutic target: from structural basis to inhibitor discovery in human diseases — Europe PMC PMID:41050403

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41050403
DOI
10.3389/fphar.2025.1640090
License (as archived)
solo-consultazione
Archived
2026-11-09T21:02:58.953Z
SHA-256 of the archived text
59238ac92f0ae8455e0ef9715902b0f9eef594475c56d7de5ad7cf9a65080eb4
Stable URL of this page
https://metraipolis.com/documento/dc_cf972de85d57

How to cite

ADAM17 as a promising therapeutic target: from structural basis to inhibitor discovery in human diseases — Europe PMC PMID:41050403 — Europe PMC (en), https://europepmc.org/article/MED/41050403 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_cf972de85d57 (Metraipolis archive dc_cf972de85d57, sha256 59238ac92f0ae8455e0ef9715902b0f9eef594475c56d7de5ad7cf9a65080eb4)
BibTeX
@misc{dccf972de85d57,
  title = {ADAM17 as a promising therapeutic target: from structural basis to inhibitor discovery in human diseases — Europe PMC PMID:41050403},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41050403},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_cf972de85d57; sha256 59238ac92f0ae8455e0ef9715902b0f9eef594475c56d7de5ad7cf9a65080eb4},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41050403. Agents can read the archived copy with the MCP tool read_document.